Total Pancreatectomy and Islet Cell Autotransplantation: Outcomes, Controversies and New Techniques

Michal Radomski, Amer H Zureikat
Division of Surgical Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

ABSTRACT
Chronic pancreatitis is a challenging disease; the constellation of chronic abdominal pain and metabolic derangements present unique difficulties to the treating physician. Initial treatment revolves around lifestyle modification, pain control, and management of exocrine insufficiency. In refractory cases, total pancreatectomy with islet cell auto transplantation (TP-IAT) is an option for patients with diffuse disease not amenable to subtotal pancreatectomy or a decompressive (drainage) operation. This procedure aspires to alleviate pain and avoid surgically induced brittle diabetes, a morbid complication of total pancreatectomy alone. Herein, we review the indications, optimal timing, surgical outcomes and controversies for TP-IAT, focusing on recently published reports.

INTRODUCTION
Affecting approximately 0.2 – 0.6% of the population, chronic pancreatitis (CP) is an inflammatory condition characterized by irreversible, permanent and progressive fibrotic destruction of the pancreatic parenchyma which can result in chronic pain as well as endocrine and exocrine dysfunction. Total pancreatectomy with islet cell auto transplantation (TP-IAT) is an effective option in selected CP patients refractory to other treatments. In the following review, we highlight traditional and controversial indications for TP-IAT, its published outcomes to date, as well as important aspects of the surgical technique including the advent of minimally invasive approaches.

ETIOLOGY OF CHRONIC PANCREATITIS
A large number of predisposing factors and conditions can lead to CP. This list includes pancreas divisum, recurrent acute pancreatitis, autoimmune disease, congenital small pancreatic duct, trauma, hypertriglyceridemia and gallstones. Despite these many associations, alcohol abuse remains the most identifiable cause of CP in the United States. In a report by Coté et al, 45% of 539 patients with CP enrolled in the North American Pancreatitis Study-2 were found to have alcohol as the identifiable etiology [1]. These results have been corroborated by a multicenter prospective Italian report published in 2009; Frulloni et al examined 893 patients and found that heavy alcohol consumption (more than 80g of alcohol/day for more than 5 years) was the most important risk factor for CP [2]. Consequently, alcohol induced CP remains a common indication for TP [3]. Interestingly, despite alcohol’s dominant pathogenic role, less than 10% of alcohol dependent patients will develop CP, implying the interplay of other factors in disease development [4]. Currently, these susceptibility factors remain elusive, though many are postulated to be genetic in nature, and some of them have also been linked to hereditary pancreatitis [5, 6].

Hereditary pancreatitis is an uncommon cause of CP, but a frequent indication for TP-IAT. It is defined as two or more individuals with pancreatitis in two or more generations of a family, or pancreatitis associated with a known disease-causing germline mutation [7]. The latter is characterized by one of three mutations. Protease, serine, 1 (trypsin 1), also known as PRSS1, encodes the major pancreatic digestive enzyme trypsin. Gain of function mutations in this gene are responsible for most of the autosomal dominant causes of hereditary pancreatitis [8, 9]. Autosomal recessive hereditary pancreatitis is associated with mutations in SPINK1 and CFTR. SPINK1 (Serine Protease Inhibitory Kazel-type 1) encodes a trypsin inhibitor that is expressed as an acute phase reactant in acinar cells during an inflammatory process. Loss of function mutations in SPINK1 predispose patients to CP and it is thought that approximately 2% of healthy individuals carry a heterozygous mutation in SPINK1 with less than 1% of those carriers developing disease [10, 11]. Finally, mutations in CFTR (cystic fibrosis trans membrane regulator protein) are associated with both recurrent acute and chronic pancreatitis. CFTR is responsible for fluid secretion in the pancreatic duct cells and functions to “wash” the ductal environment of zymogens that are then carried into the duodenum where they are activated. Disruption of this process leads to retention of zymogens in the pancreas leading to acute and chronic pancreatitis [9, 12]. Interestingly, although hereditary pancreatitis...
Table 1: Minnesota Criteria

Section I – Definitions (Must have A, B, or C)

A. Chronic pancreatitis with chronic abdominal pain lasting for > 6 months with features consistent with pancreatitis and objective evidence by having one of the following:
   1. Morphological or functional evidence of chronic pancreatitis defined by CT imaging or ERCP evidence of pancreatitis or
   2. EUS with 6 of 9 criteria for chronic pancreatitis or
   3. At least 2 of the following:
      i. T2 weighted MRI with evidence of pancreatic fibrosis, Secretin MRCP or ERCP with findings of chronic pancreatitis
      ii. EUS with 4 of 9 criteria positive for pancreatitis
      iii. Abnormal exocrine pancreatic function tests as evidence of a peak bicarbonate less than 80

or

B. Relapsing acute pancreatitis as defined as both of the following:
   1. 3+ episodes of acute pancreatitis with ongoing episodes over 6 months
   2. No evidence of gallstone disease or other correctable etiology

or

C. Documented hereditary pancreatitis with symptoms

Section II – Indications for TP-IAT

A. Chronic pancreatitis or relapsing acute pancreatitis with severe abdominal pain resulting in one of the following:
   1. Daily or near daily narcotic dependence for more than 3 months
   2. Impaired quality of life as defined as one of the following:
      a. Job loss
      b. Decreased ability or inability to work or attend school
      c. Frequent absences from school
      d. Frequent hospitalizations
      e. Inability to participate in usual age-appropriate activities
   1. Complete evaluation with no reversible cause of chronic pancreatitis or relapsing acute pancreatitis present or untreated
   2. Unresponsive to maximal medical therapy and endoscopic therapy

Adequate islet cell function (C-peptide positive non-insulin requiring diabetes or non-diabetic)

Section III - Contraindications

1. Active alcoholism or recent alcoholism (must be abstinent for 6 mo with documented therapy)
2. Illegal drug use (must be abstinent for 6 mo with documented therapy)
3. Pancreatic cancer
4. End-stage pulmonary disease, liver cirrhosis, or severe coronary artery disease
5. Poorly controlled psychiatric illness
6. Inability to comply with a postoperative regimen
7. Patients with IPMN should not receive islet cell autotransplant outside of clinical trial

To be considered for TP-IAT, patients must meet criteria in sections I and II and have no contraindications (section III). [5]

CT, computed tomography; ERCP, endoscopic retrograde cholangiopancreatography; EUS, endoscopic ultrasonography; IPMN, intrapancreatic mucinous neoplasm; MRCP, magnetic resonance cholangiopancreatography; MRI, magnetic resonance imaging

presents relatively early, most causes of pancreatitis in children and young adults are idiopathic [13].

TREATMENT OF CHRONIC PANCREATITIS

Regardless of the cause, CP results in multiple chronic medical problems that have a significant impact on a patient’s quality of life. Sequelae include chronic pain, increased risk for developing pancreatic ductal adenocarcinoma, malabsorption/steatorrhea that leads to multiple nutritional deficiencies (exocrine dysfunction), and endocrine dysfunction leading to diabetes mellitus [14]. The most debilitating aspect of the disease is the chronic, intractable pain that is typically very difficult to manage and is multifactorial in origin [15]. Treatment often occurs in a stepwise progression; initially with dietary modification, pancreatic enzyme supplementation and non-narcotic analgesia. This usually progresses to narcotic analgesia often requiring the guidance of a pain specialist. Refractory pain results in the need for more aggressive procedures such as endoscopic pancreatic decompression [16], celiac plexus nerve blocks [17], and extracorporeal shock wave lithotripsy [18]; all of which have been met with varying success.

Surgical therapy for CP was pioneered in the 1950’s and focuses on resection of the distal pancreas and decompression of the remnant pancreatic duct. The distal pancreatectomy and splenectomy, with an end-to-end pancreaticojejunostomy was initially reported by Duval in 1954 and has since undergone multiple iterations [19]. Puestow and Gillesby modified it in 1958 by performing a longitudinal pancreaticojejunostomy, splenectomy, and distal pancreatectomy to obtain better ductal drainage [20]. However since both procedures neglected to adequately drain the pancreatic head, a purely drainage procedure was developed by Partington and Rochelle (also known as the modified Puestow-Gillesby procedure) in which the anterior surface of the pancreas and duct are incised and anastomosed from head to tail with a Roux-en-Y jejunal loop. This procedure is still the most commonly performed pancreatic decompressive operation [21, 22]. While effective pain relief can be obtained, a patient must have a dilated pancreatic duct and no evidence of a pancreatic head mass [23]. When these stipulations are not met, a high quality preoperative workup including MRI with MRCP and endoscopic ultrasound can often localize abnormal areas within a diseased pancreas, allowing for one of the subtotal pancreatectomy procedures to be performed: A duodenum-preserving pancreatic head resection (Beger procedure) [24], Frey procedure [25], or a pancreaticoduodenectomy [26-29]. These procedures allow for good pain relief for head dominant disease;
Table 2: Demographic Information for Published Series

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Center</th>
<th>No. of Patients</th>
<th>Median Age</th>
<th>M:F</th>
<th>Adult Cases</th>
<th>Pediatric Cases</th>
<th>Mean BMI</th>
<th>Indication for TP-IAT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Galvani[53]</td>
<td>2014</td>
<td>University of Arizona</td>
<td>6</td>
<td>41</td>
<td>2:4</td>
<td>ND</td>
<td>ND</td>
<td>23.2</td>
<td>Idiopathic Gallstones 50%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Gallstones 17%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sepsis 17%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Autoimmune 17%</td>
</tr>
<tr>
<td>Walsh[66]</td>
<td>2012</td>
<td>Cleveland Clinic</td>
<td>20</td>
<td>43</td>
<td>12:8</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>Idiopathic Alcohol 55%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Alcohol 17%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Familial/Hereditary 10%</td>
</tr>
<tr>
<td>Desai[55]</td>
<td>2011</td>
<td>University of Arizona</td>
<td>12</td>
<td>44</td>
<td>3:9</td>
<td>ND</td>
<td>ND</td>
<td>27.2</td>
<td>Idiopathic Pancreatic Divisum 33%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pancreatic Divisum 17%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Familial/Hereditary 16%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pancreatitis 8%</td>
</tr>
<tr>
<td>Sutherland[64]</td>
<td>2012</td>
<td>University of Minnesota</td>
<td>409</td>
<td>35</td>
<td>108:301</td>
<td>356</td>
<td>53</td>
<td>24.5</td>
<td>Idiopathic Pancreatic Divisum 50%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pancreatic Divisum 17%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Familial/Hereditary 14%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other 12%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Alcohol 7%</td>
</tr>
<tr>
<td>Ahmad[69]</td>
<td>2005</td>
<td>University of Cincinnati</td>
<td>45</td>
<td>38</td>
<td>15:30</td>
<td>ND</td>
<td>ND</td>
<td>26</td>
<td>Idiopathic Pancreatic Divisum 69%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Alcohol 18%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Trauma 4%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Familial/Hereditary 2%</td>
</tr>
<tr>
<td>Bhayani[76]</td>
<td>2014</td>
<td>NSQIP</td>
<td>191</td>
<td>40</td>
<td>48:143</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>Chronic Pancreatitis 90%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Acute Pancreatitis 7%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Benign Neoplasm 3%</td>
</tr>
<tr>
<td>Wilson[57]</td>
<td>2013</td>
<td>University of Cincinnati</td>
<td>14</td>
<td>16</td>
<td>7:7</td>
<td>0</td>
<td>14</td>
<td>21.8</td>
<td>Idiopathic Familial/Hereditary 57%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pancreatic Divisum 43%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CFTR 29%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>SPINK1 7%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PRSS1 7%</td>
</tr>
<tr>
<td>Garcea[66, 77]</td>
<td>2013</td>
<td>University Hospitals of</td>
<td>50</td>
<td>43</td>
<td>24:26</td>
<td>ND</td>
<td>ND</td>
<td>21</td>
<td>Alcohol 36%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Leicester</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Unknown Gallstones 48%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Other 6%</td>
</tr>
<tr>
<td>Argo[78]</td>
<td>2008</td>
<td>University of Alabama</td>
<td>26</td>
<td>44</td>
<td>14:12</td>
<td>ND</td>
<td>ND</td>
<td>22.3</td>
<td>Alcohol 35%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Idiopathic 31%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pancreatic Divisum 23%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hypertriglyceridemia 4%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Trauma 4%</td>
</tr>
<tr>
<td>Morgan[79]</td>
<td>2011</td>
<td>Medical University of</td>
<td>33</td>
<td>42</td>
<td>8:25</td>
<td>33</td>
<td>0</td>
<td>27</td>
<td>Alcohol 42%</td>
</tr>
<tr>
<td></td>
<td></td>
<td>South Carolina</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Idiopathic 24%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Alcohol 12%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pancreatic Divisum 9%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Familial/Hereditary 9%</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Medication 3%</td>
</tr>
</tbody>
</table>

ND, Not Discussed; NSQIP, National Surgical Quality Improvement Program
however, recurrence of pain is common and occurs in up to 50% of patients [23]. If preoperative imaging reveals diffuse small duct disease, or if any of the above procedures ultimately fail, a total pancreatectomy with or without islet cell auto transplantation becomes a reasonable option. **TOTAL PANCREATECTOMY WITH ISLET CELL AUTOTRANSPLANTATION**

First reported at the University of Minnesota in 1977, the rational for performing TP-IAT is removal of the inflammatory source (and future cancer risk) while simultaneously harvesting and reintroducing the islet cells to maintain endocrine function. Directed resection (Whipple vs. subtotal pancreatectomy) is clearly the preferred method of treatment for disease that can be localized to the head or body/tail of the pancreas; however, TP-IAT has become a feasible option for patients with diffuse small duct disease who are not yet insulin dependent [30, 31].

TP-IAT has the distinct advantage of allowing patients the ability to avoid the significant postoperative complication of surgically induced brittle diabetes [30]. The severity of brittle diabetes, a condition in which a patient experiences both severe hyper and hypoglycemic episodes, should not be underestimated; in one early series, 50% of late deaths after TP were secondary to iatrogenic hypoglycemic episodes [32]. Although total pancreatectomy in the era of modern endocrine and exocrine replacement therapy has witnessed improvements in long-term morbidity and mortality, it remains one of the most morbid abdominal operations performed today [33-38].

**Indications for TP-IAT**

The classical indication for TP-IAT is CP leading to intractable abdominal pain that leads to an impaired quality of life. Patients must have failed other treatment strategies, and have preserved islet cell function. Preoperative considerations that warrant extensive patient discussion include the irreversibility of the operation, possible pain recurrence (10-20%), incomplete or variable diabetic protection, risk of serious life threatening complications and potential for gastric motility dysfunction [39]. Importantly, a multidisciplinary approach utilizing the expertise of surgeons, pain specialists, gastroenterologists, endocrinologists, psychologists, and social workers must be utilized. Patients should preferably have a strong support network as they must be able to adhere to strict postoperative medical management; consequently, any active psychosocial issues such as alcohol use represent a contraindication to the procedure.

Although IAT is performed for a number of etiologies, patients with hereditary pancreatitis will likely derive the most benefit since their pain is unlikely to abate without intervention, their symptoms are more severe, and disease onset occurs at an earlier age. Furthermore, this subset of patient’s harbors an elevated risk of pancreatic ductal adenocarcinoma, is usually healthier with less comorbidities, and lacks the psychosocial disturbances and malnutrition seen with CP secondary to alcoholism. In patients with alcoholic CP, TP-IAT has been met with varying success. Based on their analysis of 30 cases, Dunderdale et al argue that the procedure should not be performed in this subset of CP patients. In their study, TP-IAT was associated with a 23% islet cell isolation failure rate, a lower islet cell yield (1,265 vs 2,189 IEQ/kg), reduced quality of life (SF-36 and McGill Pain Questionnaire) scores at 2 years, and an increased postoperative insulin requirement when compared to patients undergoing TP-IAT for nonalcoholic CP [40]. Consequently, enthusiasm for performing such a complex and costly procedure for this patient population has diminished.

Currently, the indications and contraindications for TP-IAT are defined by the Minnesota Criteria (Table 1). It should be noted however that TP-IAT has also been reported in patients without CP, leading some to call for the expansion of those indications. For instance, TP-IAT has been performed for autoimmune pancreatitis resistant to steroid therapy [41], patients with cystic and benign neoplasms [42, 43], those with ampullary adenocarcinoma [44], and in the setting of pancreatic trauma [45, 46].

Of special interest is the use of TP-IAT for the treatment of pancreatic neoplasms. While strongly contraindicated by the Minnesota Criteria due to the fear of iatrogenic dissemination of neoplasia, a recent study by Balzano et al in which 31 malignant cases underwent TP-IAT is provocative. Of the 31 patients, 14 had neoplasms with no or low malignant potential (serous cystoadenomas, adenoma of the ampulla of Vater, low grade neuroendocrine tumors, mucinous cystic neoplasms with moderate dysplasia, intraductal papillary mucinous neoplasm with moderate dysplasia, and solid pseudopapillary neoplasm) and all were alive and disease free at a median follow-up of 491 days. Seventeen patients had adenocarcinoma (9 of which were pancreatic); at a median follow-up of >2 years, 13 were disease-free, 2 already had liver metastasis at time of surgery, and 2 developed recurrence (however these recurrences were not in the liver- the site of islet cell engraftment) [47]. Despite this study, current recommendations advise against the use of islet cell auto transplantation in patients with known pancreatic or periampullary malignancy.

Other contraindications to IAT include C-peptide negative diabetes, type 1 diabetes, portal vein thrombosis (if the portal vein is the intended site of islet cell auto transplantation), liver disease, or high-risk cardiopulmonary disease [39].

**Optimal Timing of TP-IAT**

The optimal timing for performing TP-IAT is less controversial, with most investigators supporting earlier treatment when possible [39]. The ideal timing should result in resolution of symptoms prior to the development

$$\Delta PP = 1.27 + 89.7X - 130.4(X - 0.13815)^2$$

$$X = TV/kg$$

*Figure 1. Formula for estimating change in portal pressure with a given tissue volume (X) to be infused [54].*
of central sensitization and opioid-induced hyperalgesia, which can otherwise lead to chronic pain recurrence after TP. Residual islet function and islet cell yield should also be factored in when considering timing of TP-IAT; both presumed to be superior earlier in disease [39]. In a study of 18 pediatric TP-IAT patients, Kobayashi found that fibrosis and acinar atrophy, previous ductal drainage surgeries, and longer duration of CP negatively affected islet cell yield. These findings were reaffirmed with a recent large report from the same institution [48, 49].

Recently published data evaluating TP-IAT in 75 children had reduced post op complications and a higher chance of insulin independence compared to their older counterparts [49]. New preoperative MRI imaging techniques that aim to specifically assess the viability of islet cells and predict islet cell yield may help guide optimal operative timing in the near future [50].

**Surgical Considerations**

The surgical approach to TP-IAT has gradually evolved over the past decade, but the core tenets of the procedure still hold true; minimization of pancreatic trauma during dissection and preservation of the arterial blood supply until extirpation of the organ. Both principles minimize warm ischemic time and are believed to result in higher rates of engraftment have been proposed, however their clinical use has been limited [61].

Due to these challenges, other alternative sites for islet cell engraftment have been proposed, however their clinical use has been limited [59, 63]. At this time, no convincing data exists to support many of these differences in surgical techniques, and technical decisions are usually based on the preference and experience of the operating surgeon.

**Outcomes of TP-IAT**

Multiple reports have now confirmed the safety and feasibility of TP-IAT [64, 65]. Additionally, the beneficial

**Table 3: Operative Information for Published Series**

<table>
<thead>
<tr>
<th>Author</th>
<th>Operative Route</th>
<th>Islet Cell Infusion Site</th>
<th>Islet Isolation Time (min)</th>
<th>OR Time (min)</th>
<th>EBL (mL)</th>
<th>IE/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>Galvani</td>
<td>Robotic TP-IAT</td>
<td>SV Stump</td>
<td>272.6</td>
<td>717</td>
<td>630</td>
<td>2301 ± 1545</td>
</tr>
<tr>
<td>Walsh</td>
<td>Open TP-IAT</td>
<td>SV Stump</td>
<td>480-600</td>
<td>ND</td>
<td>ND</td>
<td>3846 (3060-5430)</td>
</tr>
<tr>
<td>Desai</td>
<td>Open TP-IAT</td>
<td>SV Stump</td>
<td>250</td>
<td>637.2</td>
<td>641.7</td>
<td>2538.2 (104.2-13573)</td>
</tr>
<tr>
<td>Sutherland</td>
<td>Open TP-IAT, 1 Robotic TP-IAT</td>
<td>ND</td>
<td>210-390</td>
<td>ND</td>
<td>ND</td>
<td>3260 in last 250 cases</td>
</tr>
<tr>
<td>Ahmad</td>
<td>Open TP-IAT</td>
<td>PV (12 patients)</td>
<td>240</td>
<td>533</td>
<td>563</td>
<td>3799 ± 629 in ID patients</td>
</tr>
<tr>
<td>Bhayani</td>
<td>Open TP-IAT</td>
<td>ND</td>
<td>ND</td>
<td>530</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>Wilson</td>
<td>Open TP-IAT</td>
<td>PV</td>
<td>ND</td>
<td>531.9</td>
<td>ND</td>
<td>7436 (3203-11919)</td>
</tr>
<tr>
<td>Garcea</td>
<td>Open TP-IAT</td>
<td>UV</td>
<td>ND</td>
<td>480</td>
<td>600*</td>
<td>ND</td>
</tr>
<tr>
<td>Argo</td>
<td>Open TP-IAT or Completion</td>
<td>PV MCV</td>
<td>ND</td>
<td>414</td>
<td>632.6</td>
<td>1331 ± 304</td>
</tr>
<tr>
<td>Morgan</td>
<td>Pancreatectomy with IAT</td>
<td>ND</td>
<td>275</td>
<td>245</td>
<td>679</td>
<td>ND</td>
</tr>
</tbody>
</table>

ND, Not Discussed; SV, Splenic Vein; Portal Vein; MCV, Middle Colic Vein; II, Insulin independent; ID, Insulin Dependent; UV, umbilical vein *Reported for 45 patients
<table>
<thead>
<tr>
<th>Author</th>
<th>Follow Up (mo)</th>
<th>Glucose Control</th>
<th>Pain Control</th>
<th>LOS (d)</th>
<th>Transfusion Required (%)</th>
<th>Reoperation Required (%)*</th>
<th>Overall Complication Rate (%)**</th>
<th>Deaths</th>
</tr>
</thead>
<tbody>
<tr>
<td>Galvani[53]</td>
<td>1</td>
<td>ND</td>
<td>5 Patients weaning off narcotics</td>
<td>12.6</td>
<td>17</td>
<td>None</td>
<td>83.3</td>
<td>0</td>
</tr>
<tr>
<td>Walsh[66]</td>
<td>12</td>
<td>PostOp Insulin dose at median follow up of 12 mo (U/day) 11.6</td>
<td>PreOp ME/day 89.2</td>
<td>PostOp ME/day at median follow up of 12 mo 78</td>
<td>12</td>
<td>ND</td>
<td>25</td>
<td>45</td>
</tr>
<tr>
<td>Desai[55]</td>
<td>1</td>
<td>ND</td>
<td>ND</td>
<td>16</td>
<td>50</td>
<td>ND</td>
<td>33.3</td>
<td>0</td>
</tr>
<tr>
<td>Sutherland[63]</td>
<td>&gt; 36</td>
<td>IE/kg Transplanted</td>
<td>Percent at 36 mo follow up</td>
<td>12 II</td>
<td>33 PF</td>
<td>55 ID</td>
<td>22 II</td>
<td>62 PF</td>
</tr>
<tr>
<td>Ahmad[69]</td>
<td>18</td>
<td>Insulin Dose (U/day)</td>
<td>Percent at median of 18 mo</td>
<td>0</td>
<td>40</td>
<td>20</td>
<td>24</td>
<td>20</td>
</tr>
<tr>
<td>Bhayan[61]</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>ND</td>
<td>13</td>
<td>20</td>
<td>ND</td>
<td>59.2</td>
</tr>
<tr>
<td>Wilson[57]</td>
<td>9</td>
<td>Insulin Dose (U/day)</td>
<td>Percent at median of 9 mo</td>
<td>0</td>
<td>29</td>
<td>29</td>
<td>29</td>
<td>14</td>
</tr>
<tr>
<td>Garcea[60, 77]</td>
<td>11.5</td>
<td>Insulin Dose (U/day)</td>
<td>Percent at median of 11.5 mo</td>
<td>0</td>
<td>18.6</td>
<td>ND</td>
<td>ND</td>
<td>11.5 mo</td>
</tr>
</tbody>
</table>

** Median insulin requirements of 22U/day

* PostOp ME/day at median follow up of 12 mo

** PostOp ME/day at median follow up of 9 mo

PostOp ME/day at median follow up of 11.5 mo

11 (79%) patients narcotic independent

26 (58%) patients narcotic independent
impact of the procedure on the quality of life for CP patients is well documented (Tables 2-4) [56, 64, 66-68]. The largest series of open TP-IATs to date has been reported by Sutherland et al at the University of Minnesota, analyzing 412 TP-IATs (355 adults and 53 children) from 1977 until 2011 [64]. The authors found insulin independence and partial islet cell function to be highly dependent upon the islet equivalents per kilogram transplanted. Impressively, at 3 years, patients who received > 5,000 IE/kg had an insulin independence rate of 72%, a partial function rate of 24%, with only 4% being insulin dependent. SF-36 survey scores, which report the health status profile of a patient along 8 separate categories, were analyzed for cases performed after 2007. At 2 years post TP-IAT, scores across all categories were significantly higher. Additionally, patient’s perceptions of their health status was improved in 84% of cases at 1 year, and in 57% of patients at 2 years. Furthermore, at 2 years post TP-IAT, 59% of patients were narcotic independent.

Another large series from the University of Cincinnati by Ahmad and colleagues reporting on 45 TP-IAT’s over 4 years, also found that insulin independence correlated with IE/kg infused on univariate analysis (p=0.04) [69]. Patients that were insulin independent (40% at 18 months) received a mean IE/kg of 6635 compared to 3799 in the insulin dependent group. Regarding pain control, the results of the Cincinnati series correlate strikingly with the Minnesota series in that 58% of patients were narcotic independent post TP-IAT. In a recent follow up study from the same institution, Wilson et al analyzed the results of TP-IAT in 14 children, and found 79% of them to be narcotic independent at follow up. Only 29% of patients however were insulin independent at the same time [57].

Table 3 and 4 illustrate outcomes associated with the largest reported TP-IAT series to date.

Minimally Invasive TP-IAT

The aim of applying minimally invasive techniques to TP-IAT is to replicate the benefits seen with laparoscopic and robotic pancreatic resections: namely reduced blood loss, shorter recovery, quicker return to function, and improved quality of life. Various reports of laparoscopic TP have recently surfaced, indicating that the operation can be done with equivalent outcomes to historic controls [51, 52, 70-74]. Laparoscopic TP-IAT however, has yet to be reported.

Most recently, Galvani et al reported a case series of six patients undergoing TP-IAT using the robotic platform [53]. The authors were able to perform the procedure in pure minimally invasive fashion while simultaneously keeping warm ischemia time down to a minimum; an operative hallmark of the open approach. Operative time, blood loss, and islet cell yield were comparable to a recently published open case series of 12 patients by Desai et al [55]. The comparison of these two studies is significant since Galvani’s case series is a robotic adaptation of Desai’s technique, which was the first to describe the extirpation of the whole pancreas without dividing the pancreatic neck [53].
Authors Experience with Minimally Invasive TP-IAT
At our center, most TP-IATs are performed using the open approach. We prefer a pylorus preserving TP (no division of the pancreatic neck) with splenectomy, Roux-en-Y hepaticojejunostomy, and gastrojejunostomy. We favor islet cell infusion via a short splenic vein stump. Additionally, we are increasingly utilizing the robotic platform to perform complex pancreatic resections and reconstructions. Similar to the report by Galvani et al, we have also established the safety and feasibility of performing robotic TP with or without IAT (TP=10 patients, TP-IAT=3) [54]. All 3 IATs were performed without conversion while adhering to principles of the open approach; namely, avoiding division of the pancreatic neck and minimizing warm ischemia time. Results from the TP-IAT were encouraging, with a mean operative time (including islet cell preparation) of 600 minutes, mean EBL of 600 mL, and a mean LOS of 10.7 days (personal observation, corresponding author). Islet cell yields (mean 4563 IE/kg) were equivalent to historic controls. No mortality or major morbidity was recorded.

The addition of robotics however, may impact the cost of an already costly procedure. A cost analysis for TP-IAT in 60 patients at Leicester University revealed TP-IAT to be approximately £10,000 more expensive than TP without IAT [68]. This is likely to increase further when the cost of robotics is included. Despite this downfall, this cost burden may be offset if the benefits of robotic TP-IAT parallel those seen for other minimally invasive procedures in terms of post operative recovery and quality of life assessment.

CONCLUSION
Total pancreatectomy and islet cell auto transplantation has proven to be effective in improving the quality of life for patients suffering from chronic pancreatitis refractory to other treatments. However, due to the need for highly specialized infrastructure and expertise, it is only available at a small number of centers worldwide. While indications for TP-IAT continue to evolve, careful patient selection and early patient referral are important factors in optimizing outcomes. The application of newer technologies including robotics may reduce the morbidity associated with TP, however a detailed and rigorous assessment of these platforms is yet to be performed.

Conflict of Interest
Authors have no conflicts of interest

References


70. Mokhtari A, Karcz WK, Hopt UT, Leck T. [Laparoscopically assisted total pancreatectomy: feasible minimally invasive alternative to open resection.]. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen 2014. [PMID: 24824001]

